+
Skip to main content

Advertisement

Springer Nature Link
Log in

Positron emission tomography (PET) radiotracers for prostate cancer imaging

  • Special Section: Male pelvis
  • Published:
Abdominal Radiology Aims and scope Submit manuscript

Abstract

Imaging plays an increasing role in prostate cancer diagnosis and staging. Accurate staging of prostate cancer is required for optimal treatment planning. In detecting extraprostatic cancer and sites of early recurrence, traditional imaging methods (computed tomography, magnetic resonance imaging, radionuclide bone scan) have suboptimal performance. This leaves a gap between known disease recurrence as indicated by rising prostate-specific antigen and the ability to localize the recurrence on imaging. Novel positron emission tomography (PET) agents including radiolabeled choline, fluciclovine (18F-FACBC), and agents targeting prostate-specific membrane antigen are being developed and tested to increase diagnostic performance of non-invasive prostate cancer localization. When combined with CT or MRI, these tracers offer a combination of functional information and anatomic localization that is superior to conventional imaging methods. These PET radiotracers have varying mechanisms and excretion patterns affecting their pharmacokinetics and diagnostic performance, which will be reviewed in this article.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2019. 2019. 69(1): p. 7-34.

    Google Scholar 

  2. Li, R., et al., The use of PET/CT in prostate cancer. Prostate Cancer and Prostatic Diseases, 2018. 21(1): p. 4-21.

    PubMed  Google Scholar 

  3. De Bruycker, A., et al., Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy. 2017. 120(6): p. 815-821.

  4. Giannarini, G., et al., Will Image-guided Metastasis-directed Therapy Change the Treatment Paradigm of Oligorecurrent Prostate Cancer? European Urology, 2018. 74(2): p. 131-133.

    PubMed  Google Scholar 

  5. Jadvar, H., Molecular imaging of prostate cancer: PET radiotracers. AJR. American journal of roentgenology, 2012. 199(2): p. 278-291.

    PubMed  PubMed Central  Google Scholar 

  6. Bednarova, S., et al., Positron emission tomography (PET) in primary prostate cancer staging and risk assessment. 2017, 2017. 6(3): p. 413-423.

  7. Almuhaideb, A., N. Papathanasiou, and J. Bomanji, 18F-FDG PET/CT imaging in oncology. Annals of Saudi medicine, 2011. 31(1): p. 3-13.

    PubMed  PubMed Central  Google Scholar 

  8. Jadvar, H., FDG PET in Prostate Cancer. PET clinics, 2009. 4(2): p. 155-161.

    PubMed  PubMed Central  Google Scholar 

  9. Picchio, M., et al., Value of [11C]choline-Positron Emission Tomography for Re-Staging Prostate Cancer: A Comparison With [18F]fluorodeoxyglucose-Positron Emission Tomography. The Journal of Urology, 2003. 169(4): p. 1337-1340.

    CAS  PubMed  Google Scholar 

  10. Ackerstaff, E., et al., Detection of Increased Choline Compounds with Proton Nuclear Magnetic Resonance Spectroscopy Subsequent to Malignant Transformation of Human Prostatic Epithelial Cells. 2001. 61(9): p. 3599-3603.

    CAS  Google Scholar 

  11. Wallitt, K.L., et al., Clinical PET Imaging in Prostate Cancer. 2017. 37(5): p. 1512-1536.

    Google Scholar 

  12. Umbehr, M.H., et al., The Role of 11C-Choline and 18F-Fluorocholine Positron Emission Tomography (PET) and PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis. European Urology, 2013. 64(1): p. 106-117.

    PubMed  Google Scholar 

  13. Cimitan, M., et al., [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. European Journal of Nuclear Medicine and Molecular Imaging, 2006. 33(12): p. 1387-1398.

    PubMed  Google Scholar 

  14. Jadvar, H., Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2011. 52(1): p. 81-89.

    Google Scholar 

  15. Fuccio, C., et al., Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy. Annals of Nuclear Medicine, 2010. 24(6): p. 485-492.

    CAS  PubMed  Google Scholar 

  16. Hövels, A.M., et al., The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clinical Radiology, 2008. 63(4): p. 387-395.

    PubMed  Google Scholar 

  17. Evangelista, L., et al., Choline PET or PET/CT and Biochemical Relapse of Prostate Cancer: A Systematic Review and Meta-Analysis. 2013. 38(5): p. 305-314.

    PubMed  Google Scholar 

  18. Guo, Y., et al., Diagnostic performance of choline PET/CT for the detection of bone metastasis in prostate cancer: A systematic review and meta-analysis. PLOS ONE, 2018. 13(9): p. e0203400.

    PubMed  PubMed Central  Google Scholar 

  19. Giovacchini, G., et al., Predictive factors of [11C]choline PET/CT in patients with biochemical failure after radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2010. 37(2): p. 301-309.

    PubMed  Google Scholar 

  20. Castellucci, P., et al., Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? European Journal of Nuclear Medicine and Molecular Imaging, 2011. 38(1): p. 55-63.

  21. Sakata, T., et al., L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathology International, 2009. 59(1): p. 7-18.

    CAS  PubMed  Google Scholar 

  22. Oka, S., et al., A preliminary study of anti-1-amino-3-F-18-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer. Journal of Nuclear Medicine, 2007. 48(1): p. 46-55.

    CAS  PubMed  Google Scholar 

  23. Savir-Baruch, B., et al., Fluorine-18-Labeled Fluciclovine PET/CT in Clinical Practice: Factors Affecting the Rate of Detection of Recurrent Prostate Cancer. American Journal of Roentgenology, 2019: p. 1-8.

  24. Odewole, O.A., et al., Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT. Eur J Nucl Med Mol Imaging, 2016. 43(10): p. 1773-83.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Kim, S.J. and S.W. Lee, The role of 18F-fluciclovine PET in the management of prostate cancer: a systematic review and meta-analysis. Clinical Radiology, 2019.

  26. Turkbey, B., et al., Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis. Radiology, 2014. 270(3): p. 849-56.

    PubMed  Google Scholar 

  27. Selnaes, K.M., et al., (18)F-Fluciclovine PET/MRI for preoperative lymph node staging in high-risk prostate cancer patients. Eur Radiol, 2018. 28(8): p. 3151-3159.

    PubMed  Google Scholar 

  28. Pernthaler, B., et al., A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68 Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT. 2019. 44(10): p. e566-e573.

  29. Nanni, C., et al., 18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT. 2015. 40(8): p. e386-e391.

  30. Wright, G.L., et al., Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urologic Oncology: Seminars and Original Investigations, 1995. 1(1): p. 18-28.

    PubMed  Google Scholar 

  31. Martin, K.B., et al., Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. Endocrine-Related Cancer, 2019. 26(2): p. 131-146.

    Google Scholar 

  32. Prasad, V., et al., Biodistribution of [68 Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions. Molecular Imaging and Biology, 2016. 18(3): p. 428-436.

    CAS  PubMed  Google Scholar 

  33. Koerber, S.A., et al., (68)Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 Patients. J Nucl Med, 2018.

  34. Calais, J., et al., (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol, 2019. 20(9): p. 1286-1294.

    CAS  PubMed  Google Scholar 

  35. Afshar-Oromieh, A., et al., Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging, 2017. 44(8): p. 1258-1268.

    PubMed  PubMed Central  Google Scholar 

  36. Fendler, W.P., et al., Assessment of 68 Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol, 2019. 5(6): p. 856-863.

    PubMed  PubMed Central  Google Scholar 

  37. Afshar-Oromieh, A., et al., Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Med Mol Imaging, 2018. 45(12): p. 2045-2054.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Sterzing, F., et al., 68 Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2016. 43(1): p. 34-41.

    CAS  PubMed  Google Scholar 

  39. Gorin, M.A., M.G. Pomper, and S.P. Rowe, PSMA-targeted imaging of prostate cancer: the best is yet to come. 2016. 117(5): p. 715-716.

    Google Scholar 

  40. Sanchez-Crespo, A., Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography. Applied Radiation and Isotopes, 2013. 76: p. 55-62.

    CAS  PubMed  Google Scholar 

  41. Dietlein, M., et al., Comparison of [18F]DCFPyL and [68 Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. Molecular Imaging and Biology, 2015. 17(4): p. 575-584.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Czarniecki, M., et al., Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents. 2018, 2018. 7(5): p. 831-843.

  43. Rowe, S.P., et al., Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naive and Castration-Resistant Metastatic Prostate Cancer. J Nucl Med, 2016. 57(1): p. 46-53.

    CAS  PubMed  Google Scholar 

  44. Harmon, S.A., et al., A Prospective Comparison of (18)F-Sodium Fluoride PET/CT and PSMA-Targeted (18)F-DCFBC PET/CT in Metastatic Prostate Cancer. J Nucl Med, 2018. 59(11): p. 1665-1671.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Wondergem, M., et al., 18F-DCFPyL PET/CT in primary staging of prostate cancer. 2018. 2(1): p. 26.

  46. Rowe, S.P., et al., Prospective Evaluation of PSMA-Targeted (18)F-DCFPyL PET/CT in Men with Biochemical Failure after Radical Prostatectomy for Prostate Cancer. J Nucl Med, 2019.

  47. Rowe, S.P., et al., PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. Molecular Imaging and Biology, 2016. 18(3): p. 411-419.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Giesel, F.L., et al., Detection Efficacy of (18)F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. J Nucl Med, 2019. 60(3): p. 362-368.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Kesch, C., et al., Intra-individual comparison of (18)F-PSMA-1007-PET/CT, multi-parametric MRI and radical prostatectomy specimen in patients with primary prostate cancer - a retrospective, proof of concept study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017. 58.

  50. Werner, R.A., et al., 18 F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging. Theranostics, 2020. 10(1): p. 1-16.

    PubMed  PubMed Central  Google Scholar 

  51. Dietlein, M., et al., Performance of the novel 18F-labeled prostate-specific membrane antigen-ligand PSMA-7 for PET/CT in prostate cancer patients. 2018. 59(supplement 1): p. 452.

  52. Behr, S.C., et al., First-in-Human Phase I study of CTT1057, a Novel 18F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer. 2018.

  53. Saga, T., et al., Initial evaluation of PET/CT with 18F‐FSU‐880 targeting prostate‐specific membrane antigen in prostate cancer patients. 2019. 110(2): p. 742.

  54. Alonso, O., et al., PET/CT evaluation of prostate cancer patients with Al18F-PSMA-HBED-CC: a head-to-head comparison with 68 Ga-PSMA-HBED-CC. 2018. 59(supplement 1): p. 1499-1499.

  55. Fraum, T.J., et al., Prostate cancer PET tracers: essentials for the urologist. Can J Urol, 2018. 25(4): p. 9371-9383.

    PubMed  Google Scholar 

  56. Czernin, J., N. Satyamurthy, and C. Schiepers, Molecular mechanisms of bone 18F-NaF deposition. J Nucl Med, 2010. 51(12): p. 1826-9.

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Sheikhbahaei, S., et al., 18F-NaF-PET/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies. Annals of Nuclear Medicine, 2019. 33(5): p. 351-361.

    CAS  PubMed  Google Scholar 

  58. Chen, B., et al., Comparison of 18F-Fluciclovine PET/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer. 2019. 40(9): p. 940-946.

  59. Beheshti, M., et al., Evaluation of Prostate Cancer Bone Metastases with 18F-NaF and 18F-Fluorocholine PET/CT. J Nucl Med, 2016. 57(Suppl 3): p. 55S-60S.

    CAS  PubMed  Google Scholar 

  60. Schirrmeister, H., Detection of bone metastases in breast cancer by positron emission tomography. Radiol Clin North Am, 2007. 45(4): p. 669-76, vi.

  61. Jadvar, H. and P.M. Colletti, 18F-NaF/223RaCl2 theranostics in metastatic prostate cancer: treatment response assessment and prediction of outcome. The British Journal of Radiology, 2018. 91(1091): p. 20170948.

    PubMed  PubMed Central  Google Scholar 

  62. Poeppel, T.D., et al., 68 Ga-DOTATOC versus 68 Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med, 2011. 52(12): p. 1864-70.

    CAS  PubMed  Google Scholar 

  63. Morichetti, D., et al., Immunohistochemical expression and localization of somatostatin receptor subtypes in prostate cancer with neuroendocrine differentiation. Int J Immunopathol Pharmacol, 2010. 23(2): p. 511-22.

    CAS  PubMed  Google Scholar 

  64. Gofrit, O.N., et al., PET/CT With 68 Ga-DOTA-TATE for Diagnosis of Neuroendocrine: Differentiation in Patients With Castrate-Resistant Prostate Cancer. 2017. 42(1): p. 1-6.

  65. dos Santos, G., et al., Comparación intraindividual de la PET/TC con 68 Ga-DOTATATE vs. PET/TC con 11C-colina en pacientes con cáncer de próstata en recaída bioquímica: evaluación in vivo de la expresión de receptores de la somatostatina. Revista Española de Medicina Nuclear e Imagen Molecular, 2019. 38(1): p. 29-37.

  66. Wang, J., 68 Ga-DOTATATE in Benign Prostate Hyperplasia. 2019. 44(3): p. 249-250.

Download references

Funding

This research is funded by intramural research program of NIH.

Author information

Authors and Affiliations

  1. Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA

    Stephanie M. Walker, Ilhan Lim, Liza Lindenberg, Esther Mena, Peter L. Choyke & Baris Turkbey

  2. Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul, Korea

    Ilhan Lim

Authors
  1. Stephanie M. Walker
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Ilhan Lim
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Liza Lindenberg
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Esther Mena
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Peter L. Choyke
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Baris Turkbey
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Baris Turkbey.

Ethics declarations

Conflict of interest

The authors have no disclosures.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Walker, S.M., Lim, I., Lindenberg, L. et al. Positron emission tomography (PET) radiotracers for prostate cancer imaging. Abdom Radiol 45, 2165–2175 (2020). https://doi.org/10.1007/s00261-020-02427-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00261-020-02427-4

Keywords

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载